A Phase 3 interventional study of Tacrolimus (reduced tacrolimus) and Everolimus (reduced tacrolimus) in Liver Transplant Recipient, sponsored by Novartis Pharmaceuticals. Completed at 57 sites in 16 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients. The most important long-term safety assessments include evaluation of renal function, progression of HCV related allograft fibrosis, and other treatment related effects at Month 36 post-transplantation compared to extension baseline (Months 24 post-transplantation).
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
Drug: Tacrolimus (reduced tacrolimus) · Drug: Everolimus (reduced tacrolimus) · Drug: Corticosteroids
Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
Drug: Tacrolimus (tacrolimus elimination) · Drug: Everolimus (tacrolimus elimination) · Drug: Corticosteroids
Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
Drug: Tacrolimus (tacrolimus control) · Drug: Corticosteroids
After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic
Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
Also known as: RAD001,, Zortress,, Certican,, Afinitor
After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic
Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
Also known as: RAD001,, Zortress,, Certican,, Afinitor
Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
Also known as: FK-506,, fujimycin,, Prograf,, Advagraf,, Protopic
For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death
The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
Time frame: from months 24 to 36
Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death
The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
Time frame: from months 36 to 48
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death
The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
Time frame: from months 24 to 36
Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death
The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
Time frame: from months 36 - 48
Change in Renal Function
Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m\^2) = 186.3\*(C\^-1.154)\*(A\^-0.203)\*G\*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.
Time frame: from months 24 to 36
Incidence Rate of tBPAR
The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.
Time frame: from months 24 - 36
Two hundred eight four participants were eligible and enrolled into the extension. However, 2 participants withdrew from the extension prior to receiving treatment. Therefore, a total of 282 participants were accounted for in the extension.
| Milestone | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Started | 106 | 51 | 125 |
| Completed | 96 | 49 | 117 |
| Not completed | 10 | 2 | 8 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Administrative problems | 5 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 | 3 |
| Milestone | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Started | 106 | 51 | 0 |
| Completed | 95 | 47 | 0 |
| Not completed | 11 | 4 | 0 |
| Withdrew: Administrative problems | 5 | 4 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 |
The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
| Participants | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death | 2 | 1 | 3 |
The number of participants who experienced composite efficacy failure was analyzed. Composite efficacy failure was defined as treated biopsy proven acute rejection (tBPAR), graft loss, or death. A BPAR was defined as an acute rejection confirmed by biopsy with a Rejection Activity Index (RAI) score ≥ 3. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
| Participants | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination |
|---|---|---|
| Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death | 1 | 0 |
The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
| Participants | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death | 2 | 0 | 1 |
The number of participants who experienced graft loss or death was analyzed. The graft was presumed to be lost on the day the patient was newly listed for a liver graft, received a graft re-transplant, or died.
| Participants | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination |
|---|---|---|
| Incidence Rate of Composite Efficacy Failure Defined as Graft Loss or Death | 0 | 0 |
The number of participants who had a tBPAR was analyzed. tBPAR was defined as a BPAR which was treated with anti-rejection therapy. The RAI is used to score liver biopsies with acute rejection and is composed of 3 categories (portal inflammation, bile duct inflammation damage, and venous endothelial inflammation) each scored on a scale of 0 (absent) to 3 (severe) by a trained pathologist. The total RAI score = the sum of the scores of the 3 categories and ranges from 0 to 9, with a higher score indicating greater rejection.
| Participants | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Incidence Rate of tBPAR | 0 | 1 | 2 |
Change in renal function was assessed by the estimated Glomerular Filtration Rate (eGFR) using the abbreviated (4 variables) Modification of Diet in Renal Disease (MDRD-4) formula which was developed by the MDRD Study Group and has been validated in patients with chronic kidney disease. The MDRD-4 formula used for the eGFR calculation is: eGFR (mL/min/1.73m\^2) = 186.3\*(C\^-1.154)\*(A\^-0.203)\*G\*R, where C is the serum concentration of creatinine (mg/dL), A is age (years), G=0.742 when gender is female, otherwise G=1, R=1.21 when race is black, otherwise R=1.
| mL/min/1.73m^2 | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control |
|---|---|---|---|
| Change in Renal Function | -0.9 ± 16.13 | 2.5 ± 12.40 | -3.3 ± 11.84 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reduced TAC, Month 36 | — | 32/106 (30.2%) | 38/106 (35.8%) |
| TAC Elimination, Month 36 | — | 16/51 (31.4%) | 29/51 (56.9%) |
| TAC Control, Month 36 | — | 28/125 (22.4%) | 43/125 (34.4%) |
| Reduced RAD + TAC, Month 48 | — | 34/106 (32.1%) | 43/106 (40.6%) |
| TAC Elimination, Month 48 | — | 24/51 (47.1%) | 36/51 (70.6%) |
| Event | Reduced TAC, Month 36 | TAC Elimination, Month 36 | TAC Control, Month 36 | Reduced RAD + TAC, Month 48 | TAC Elimination, Month 48 |
|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 3/106 | 2/51 | 2/125 | 3/106 | 4/51 |
| Incisional herniaInjury, poisoning and procedural complications | 1/106 | 2/51 | 1/125 | 2/106 | 4/51 |
| PneumoniaInfections and infestations | 2/106 | 2/51 | 3/125 | 3/106 | 3/51 |
| Impaired healingGeneral disorders | 2/106 | 1/51 | 0/125 | 2/106 | 2/51 |
| DiarrhoeaGastrointestinal disorders | 3/106 | 0/51 | 2/125 | 4/106 | 0/51 |
| Coronary artery stenosisCardiac disorders | 0/106 | 0/51 | 0/125 | 0/106 | 1/51 |
| Abdominal painGastrointestinal disorders | 1/106 | 0/51 | 1/125 | 1/106 | 1/51 |
| Abdominal strangulated herniaGastrointestinal disorders | 0/106 | 1/51 | 0/125 | 0/106 | 1/51 |
| Gastrointestinal obstructionGastrointestinal disorders | 0/106 | 0/51 | 0/125 | 0/106 | 1/51 |
| Intestinal obstructionGastrointestinal disorders | 0/106 | 0/51 | 0/125 | 0/106 | 1/51 |
| Event | Reduced TAC, Month 36 | TAC Elimination, Month 36 | TAC Control, Month 36 | Reduced RAD + TAC, Month 48 | TAC Elimination, Month 48 |
|---|---|---|---|---|---|
| Incisional herniaInjury, poisoning and procedural complications | 2/106 | 6/51 | 2/125 | 2/106 | 7/51 |
| DiarrhoeaGastrointestinal disorders | 10/106 | 3/51 | 4/125 | 13/106 | 4/51 |
| FatigueGeneral disorders | 1/106 | 2/51 | 10/125 | 2/106 | 6/51 |
| Oedema peripheralGeneral disorders | 4/106 | 4/51 | 2/125 | 6/106 | 5/51 |
| NasopharyngitisInfections and infestations | 5/106 | 5/51 | 4/125 | 6/106 | 5/51 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 6/106 | 4/51 | 3/125 | 7/106 | 5/51 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/106 | 3/51 | 0/125 | 2/106 | 5/51 |
| HypertensionVascular disorders | 8/106 | 2/51 | 5/125 | 9/106 | 2/51 |
| Renal failureRenal and urinary disorders | 1/106 | 1/51 | 10/125 | 2/106 | 1/51 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/106 | 1/51 | 1/125 | 0/106 | 4/51 |
| Age, Continuous(Years) | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control | Total |
|---|---|---|---|---|
| Mean | 53.5 ± 9.57 | 54.9 ± 10.07 | 55.2 ± 8.10 | 54.5 ± 9.25 |
| Sex: Female, Male(Participants) | Everolimus + Reduced Tacrolimus | Tacrolimus Elimination | Tacrolimus Control | Total |
|---|---|---|---|---|
| Female | 29 | 18 | 38 | 85 |
| Male | 77 | 33 | 87 | 197 |
Ran from Mar 2010 to primary completion in May 2013, 37 months.
Results were first posted in May 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus